ZFIN ID: ZDB-FISH-161216-2
Fish name: WT + MO3-nolc1
Genotype: WT
Targeting Reagent: MO3-nolc1
HUMAN DISEASE MODELED by WT + MO3-nolc1
Human Disease Conditions Citations
Treacher Collins syndrome standard conditions Rosas et al., 2019
GENE EXPRESSION
Gene expression in WT + MO3-nolc1
Reporter gene expression No data available
PHENOTYPE
Phenotype in WT + MO3-nolc1
Phenotype Conditions Figures
apoptotic process increased occurrence, abnormal standard conditions Fig. 2 with image from de Peralta et al., 2016
ceratohyal cartilage increased angle to ceratohyal cartilage, abnormal chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Fig. 3 from Rosas et al., 2019
ceratohyal cartilage increased angle to ceratohyal cartilage, abnormal standard conditions Fig. 1Fig. 3 from Rosas et al., 2019
ceratohyal cartilage increased angle to ceratohyal cartilage, ameliorated chemical treatment: bortezomib Fig. 3 from Rosas et al., 2019
cranial cartilage morphology, abnormal standard conditions Fig. 1 with imageFig. 2 with image from de Peralta et al., 2016
cranium decreased length, abnormal standard conditions Fig. 1Fig. 3 from Rosas et al., 2019
cranium decreased length, ameliorated chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Fig. 3 from Rosas et al., 2019
embryonic cranial skeleton morphogenesis disrupted, abnormal standard conditions Fig. 1 with imageFig. 2 with image from de Peralta et al., 2016
head apoptotic, abnormal standard conditions Fig. 2 with image from de Peralta et al., 2016
head apoptotic process increased frequency, abnormal control Fig. 5 from Rosas et al., 2019
head apoptotic process increased frequency, ameliorated chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Fig. 5 from Rosas et al., 2019
head apoptotic process increased frequency, ameliorated chemical treatment: bortezomib Fig. 5 from Rosas et al., 2019
hyosymplectic cartilage decreased length, abnormal standard conditions Fig. 1Fig. 3 from Rosas et al., 2019
hyosymplectic cartilage decreased length, ameliorated chemical treatment: bortezomib Fig. 3 from Rosas et al., 2019
hyosymplectic cartilage decreased length, ameliorated chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Fig. 3 from Rosas et al., 2019
Meckel's cartilage increased angle to Meckel's cartilage, abnormal standard conditions Fig. 1Fig. 3 from Rosas et al., 2019
Meckel's cartilage increased angle to Meckel's cartilage, ameliorated chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Fig. 3 from Rosas et al., 2019
Meckel's cartilage increased angle to Meckel's cartilage, ameliorated chemical treatment: bortezomib Fig. 3 from Rosas et al., 2019
palatoquadrate cartilage decreased length, abnormal standard conditions Fig. 1Fig. 3 from Rosas et al., 2019
palatoquadrate cartilage decreased length, ameliorated chemical treatment: bortezomib Fig. 3 from Rosas et al., 2019
palatoquadrate cartilage decreased length, ameliorated chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Fig. 3 from Rosas et al., 2019
pharyngeal arch cartilage morphology, abnormal control Fig. 2 from Rosas et al., 2019
pharyngeal arch cartilage morphology, ameliorated chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Fig. 2 from Rosas et al., 2019
pharyngeal arch cartilage morphology, ameliorated chemical treatment: bortezomib Fig. 2 from Rosas et al., 2019
ventral mandibular arch decreased width, abnormal control Fig. 3 from Rosas et al., 2019
ventral mandibular arch decreased width, ameliorated chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Fig. 3 from Rosas et al., 2019
ventral mandibular arch decreased width, ameliorated chemical treatment: bortezomib Fig. 3 from Rosas et al., 2019
whole organism nolc1 expression decreased amount, abnormal standard conditions Fig. 1 from Rosas et al., 2019
whole organism cnbpa expression decreased amount, abnormal standard conditions Fig. 1Fig. 4 from Rosas et al., 2019
Fig. 4 with image from de Peralta et al., 2016
whole organism pmaip1 expression increased amount, abnormal standard conditions Fig. 2 with image from de Peralta et al., 2016
whole organism cnbpa expression increased amount, abnormal chemical treatment: bortezomib Fig. 4 from Rosas et al., 2019
whole organism ccng1 expression increased amount, abnormal standard conditions Fig. 2 with image from de Peralta et al., 2016
whole organism cnbpa expression increased amount, abnormal chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Fig. 4 from Rosas et al., 2019
whole organism tp53inp1 expression increased amount, abnormal standard conditions Fig. 2 with image from de Peralta et al., 2016
whole organism reactive oxygen species increased amount, abnormal control Fig. 5 from Rosas et al., 2019
whole organism reactive oxygen species increased amount, ameliorated chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Fig. 5 from Rosas et al., 2019
whole organism reactive oxygen species increased amount, ameliorated chemical treatment: bortezomib Fig. 5 from Rosas et al., 2019

CITATIONS  (2)